• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Comment to Drs Gastaldon, Papola, Ostuzzi and Barbui.

作者信息

Mathews Maju, Daly Ella J, Popova Vanina, Heerlein Kristin, Canuso Carla, Drevets Wayne C

机构信息

Neuroscience Global Medical Affairs, Janssen Research & Development, LLC, Titusville, NJ, USA.

Department of Clinical Medical Affairs, Janssen Scientific Affairs, LLC, Titusville, NJ, USA.

出版信息

Epidemiol Psychiatr Sci. 2020 Apr 29;29:e124. doi: 10.1017/S2045796020000268.

DOI:10.1017/S2045796020000268
PMID:32345386
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7214706/
Abstract
摘要

相似文献

1
Comment to Drs Gastaldon, Papola, Ostuzzi and Barbui.致加斯塔尔东博士、帕波拉博士、奥斯特uzzi博士和巴尔比博士的评论。 （注：原文中“Ostuzzi”可能有误，推测可能是“Ostuzzi”之类的拼写错误，这里按原样翻译）
Epidemiol Psychiatr Sci. 2020 Apr 29;29:e124. doi: 10.1017/S2045796020000268.
2
Comments to Drs. Gastaldon, Raschi, Kane, Barbui, and Schoretsanitis.给加斯塔尔东博士、拉斯基博士、凯恩博士、巴尔比博士和肖雷察尼蒂斯博士的评论。
Psychother Psychosom. 2021;90(2):138-139. doi: 10.1159/000512311. Epub 2020 Oct 27.
3
Comment on a Word to the Wise About Intranasal Esketamine.关于鼻内用艾司氯胺酮的明智之言的评论
Am J Psychiatry. 2019 Oct 1;176(10):856-857. doi: 10.1176/appi.ajp.2019.19070688.
4
Intravenous ketamine for treatment-resistant major depressive disorder.静脉注射氯胺酮治疗难治性重度抑郁症。
Ann Pharmacother. 2012 Jan;46(1):117-23. doi: 10.1345/aph.1Q371. Epub 2011 Dec 20.
5
Predictors of Response to Ketamine in Treatment Resistant Major Depressive Disorder and Bipolar Disorder.治疗抵抗性重性抑郁障碍和双相障碍患者对氯胺酮反应的预测因素。
Int J Environ Res Public Health. 2018 Apr 17;15(4):771. doi: 10.3390/ijerph15040771.
6
More Thoughts on Intranasal Esketamine: Response to Drevets et al.关于鼻内艾氯胺酮的更多思考：对德雷维茨等人的回应
Am J Psychiatry. 2019 Oct 1;176(10):858-859. doi: 10.1176/appi.ajp.2019.19070688r.
7
Ketamine and Treatment-Resistant Depression.氯胺酮与难治性抑郁症
AANA J. 2019 Oct;87(5):411-419.
8
Use of Ketamine in Elderly Patients with Treatment-Resistant Depression.使用氯胺酮治疗治疗抵抗性老年抑郁症患者。
Curr Psychiatry Rep. 2017 Nov 15;19(12):107. doi: 10.1007/s11920-017-0855-x.
9
Ketamine for Treatment-Resistant Depression: a New Advocate.氯胺酮用于治疗抵抗性抑郁症：一位新的支持者。
Rev Invest Clin. 2018;70(2):65-7. doi: 10.24875/RIC.18002501.
10
Ketamine-ECT Study.
Lancet Psychiatry. 2017 Sep;4(9):662. doi: 10.1016/S2215-0366(17)30329-2.

引用本文的文献

1
Safety Profile and Suicidality Associated with the Use of Esketamine in the Treatment of Major Depressive Disorder in European Countries: An EudraVigilance Database Analysis.欧洲国家中艾司氯胺酮用于治疗重度抑郁症的安全性概况及自杀倾向：一项欧洲药品不良反应数据库分析
Pharmaceuticals (Basel). 2025 May 9;18(5):702. doi: 10.3390/ph18050702.
2
Safety and efficacy with esketamine in treatment-resistant depression: long-term extension study.艾氯胺酮治疗难治性抑郁症的安全性和有效性：长期扩展研究。
Int J Neuropsychopharmacol. 2025 Jun 6;28(6). doi: 10.1093/ijnp/pyaf027.
3
Long-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: interim results of the SUSTAIN-3 study.依他佐辛鼻喷雾剂治疗难治性抑郁症患者的长期安全性和疗效维持：SUSTAIN-3 研究的中期结果。
Neuropsychopharmacology. 2023 Jul;48(8):1225-1233. doi: 10.1038/s41386-023-01577-5. Epub 2023 May 12.
4
Esketamine clinical trials: reply to Maju .依他佐辛临床试验：回复马朱。
Epidemiol Psychiatr Sci. 2020 Apr 29;29:e122. doi: 10.1017/S204579602000027X.

本文引用的文献

1
Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression: Assessment of Long-Term Safety in a Phase 3, Open-Label Study (SUSTAIN-2).依他佐辛鼻喷剂联合口服抗抑郁药治疗难治性抑郁症患者：3 期、开放标签研究（SUSTAIN-2）的长期安全性评估。
J Clin Psychiatry. 2020 Apr 28;81(3):19m12891. doi: 10.4088/JCP.19m12891.
2
Esketamine for treatment resistant depression: a trick of smoke and mirrors?用于治疗抵抗性抑郁症的 Esketamine：烟雾与镜子的把戏？
Epidemiol Psychiatr Sci. 2019 Dec 16;29:e79. doi: 10.1017/S2045796019000751.
3
Efficacy and Safety of Esketamine Nasal Spray Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression-TRANSFORM-3.依他佐辛鼻喷剂联合口服抗抑郁药治疗老年难治性抑郁症的疗效和安全性-TRANSFORM-3。
Am J Geriatr Psychiatry. 2020 Feb;28(2):121-141. doi: 10.1016/j.jagp.2019.10.008. Epub 2019 Oct 17.
4
Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1).依他佐辛鼻喷剂固定剂量联合新型抗抑郁药治疗难治性抑郁症的疗效和安全性：一项随机、双盲、阳性对照研究（TRANSFORM-1）的结果。
Int J Neuropsychopharmacol. 2019 Oct 1;22(10):616-630. doi: 10.1093/ijnp/pyz039.
5
Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.依他佐辛鼻喷剂联合口服抗抑郁药治疗治疗抵抗性抑郁症患者预防复发的疗效：一项随机临床试验。
JAMA Psychiatry. 2019 Sep 1;76(9):893-903. doi: 10.1001/jamapsychiatry.2019.1189.
6
Esketamine for Treatment-Resistant Depression - First FDA-Approved Antidepressant in a New Class.艾氯胺酮用于治疗抵抗性抑郁症——首个获美国食品药品监督管理局批准的新型抗抑郁药。
N Engl J Med. 2019 Jul 4;381(1):1-4. doi: 10.1056/NEJMp1903305. Epub 2019 May 22.
7
Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study.灵活剂量依他佐辛鼻喷雾剂联合新起始口服抗抑郁药治疗难治性抑郁症的疗效和安全性：一项随机、双盲、活性对照研究。
Am J Psychiatry. 2019 Jun 1;176(6):428-438. doi: 10.1176/appi.ajp.2019.19020172. Epub 2019 May 21.
8
Treatment-resistant depression and suicidality.治疗抵抗性抑郁症和自杀意念。
J Affect Disord. 2018 Aug 1;235:362-367. doi: 10.1016/j.jad.2018.04.016. Epub 2018 Apr 3.
9
Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial.鼻腔内依他佐辛辅助口服抗抑郁药治疗难治性抑郁症的疗效和安全性：一项随机临床试验。
JAMA Psychiatry. 2018 Feb 1;75(2):139-148. doi: 10.1001/jamapsychiatry.2017.3739.
10
Is the significant superiority of escitalopram compared with other antidepressants clinically relevant?艾司西酞普兰与其他抗抑郁药相比的显著优势在临床上是否具有相关性？
Int Clin Psychopharmacol. 2009 May;24(3):111-8. doi: 10.1097/YIC.0b013e32832a8eb2.